# Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Source: https://onco.cc/trials/nct05770531/  
OnCo record `nct05770531` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan in triple-negative breast cancer, run by Vanderbilt-Ingram Cancer Center, now recruiting.

## Summary

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy is a phase 2, randomised interventional study registered as NCT05770531 by Vanderbilt-Ingram Cancer Center, with a registry enrolment figure of 160 participants, started 2023-10-03 and due to reach its primary completion in 2028-08-01. Interventions recorded: Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Biospecimen Collection; Sacituzumab Govitecan. Conditions listed: Metastatic HER2-Negative Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma. Triple-negative eligibility wording from the registry: "* Malignancies other than TNBC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05770531
- Phase: 2
- Setting: A Randomized Clinical Trial Comparing ctDNA-Directed Therapy Change With Standard of Care in Patients With Metastatic Triple Negative Breast Cancer
- Sponsor: Vanderbilt-Ingram Cancer Center
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT05770531: https://clinicaltrials.gov/study/NCT05770531

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05770531.json